Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2023-01-23 00:00:00 ET · period of report 2023-01-18 · accession 0001209191-23-004345 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-23 | 2023-01-18 | DYN | McNeill Jonathan | See Remarks | M - OptEx | $0.73 | +10.0K | 77.6K | +15% | +$7,300 |
| D | 2023-01-23 | 2023-01-18 | DYN | McNeill Jonathan | See Remarks | S - Sale+OE | $14.03 | -10.0K | 67.6K | -13% | -$140.3K |
| D | 2023-01-23 | 2023-01-18 | DYN | McNeill Jonathan | See Remarks | M - OptEx | $0.00 | -10.0K | 68.5K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-18 | M | A | 10,000 | $0.73 | 77,600 | D | — | — | (F1) This is an inadvertent late filing due to an administrative error. |
| 2 | Common | Common Stock | 2023-01-18 | S | D | 10,000 | $14.03 | 67,600 | D | — | — | (F1) This is an inadvertent late filing due to an administrative error. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $14.00 to $14.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. |
| 3 | Derivative | Stock Option (right to buy) | 2023-01-18 | M | D | 10,000 | $0.00 | 68,528 | D | $0.73 · — to 2029-02-25 | 10,000 Common Stock | (F1) This is an inadvertent late filing due to an administrative error. (F4) The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |